NS
CCCC icon

NBC Securities’s C4 Therapeutics CCCC Stock Holding History

NBC Securities’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.1K Buy
18,000
+14,000
+350% +$47.9K 0.01% 1128
2026
Q1 		$10.5K Hold
4,000
– – ﹤0.01% 1923
2025
Q4 		$7.64K Buy
+4,000
New +$9.48K ﹤0.01% 2095

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NBC Securities's CCCC Position: Q2 2026 in Review

NBC Securities increased its C4 Therapeutics (CCCC) stake by 350% in Q2 2026, buying an estimated $47.9K and bringing the position to 18,000 shares worth $84.1K. The position accounts for 0.01% of the portfolio, ranked #1128.

NBC Securities first reported a position in CCCC in Q4 2025 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • NBC Securities held 18,000 shares of C4 Therapeutics worth $84.1K as of Q2 2026.
  • NBC Securities bought 14,000 C4 Therapeutics shares in Q2 2026, an estimated $47.9K.
  • C4 Therapeutics made up 0.01% of NBC Securities's portfolio in Q2 2026, its #1128 holding.
  • NBC Securities first reported a position in C4 Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on NBC Securities's 13F filing for Q2 2026, filed 21 Jul 2026.